Monopar Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: MNPR · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: MNPR
TL;DR
Monopar filed an 8-K for a Reg FD disclosure, no new material info disclosed.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on March 7, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.
Why It Matters
This filing indicates Monopar Therapeutics is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- March 7, 2024 (date) — Filing date
- Regulation FD (regulation) — Disclosure type
FAQ
What is the purpose of this 8-K filing?
The purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is the filing date of this report?
The filing date of this report is March 7, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the registrant's telephone number?
The registrant's telephone number is (847) 388-0349.
What jurisdiction is Monopar Therapeutics incorporated in?
Monopar Therapeutics Inc. is incorporated in Delaware.
Filing Stats: 386 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2024-03-07 08:30:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240305_8k.htm (8-K) — 23KB
- 0001437749-24-006900.txt ( ) — 158KB
- mnpr-20240307.xsd (EX-101.SCH) — 3KB
- mnpr-20240307_def.xml (EX-101.DEF) — 12KB
- mnpr-20240307_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240307_pre.xml (EX-101.PRE) — 12KB
- mnpr20240305_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 7, 2024, Monopar Therapeutics Inc. posted their radiopharma presentation which is available under the Investor section of their website www.monopartx.com. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: March 7, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director